Navicular syndrome management changed significantly in 2014 when the U.S. Food and Drug Administration approved bisphosphonates for treatment. Sponsored by Dechra Veterinary Products.
Recently, Texas A&M researchers reviewed the current body of knowledge surrounding bisphosphonates and their use in horses. Their goal, they wrote, was to “discuss the current understanding of the strengths and weaknesses of bisphosphonates in equine veterinary medicine and highlight the future utility of these potentially highly beneficial drugs.”
Download this special report to learn what they’ve found and suggestions for pinpointing optimal use of bisphosphonates in horses going forward.